3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Acrocephalosyndactylia
5
Cholangiocarcinoma
4
Neoplasm Metastasis
3
Carcinoma, Transitional Cell
3
Recurrence
2
Urinary Bladder Neoplasms
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Unknown Primary
1
Myeloproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Glioma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Eosinophilia
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
1
osimertinib
1
durvalumab
1
AZD 6244
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Advanced Non Small Cell Lung Cancer
×
pemigatinib
×
1 year
×
Clear all
No trials found.